René Bernards
Cancer geneticist who explained why BRAF inhibitors fail in colorectal cancer, leading to the BEACON combination.
René Bernards' functional genetic screens identified EGFR feedback as the reason BRAF inhibitors fail in colorectal cancer, the rationale behind encorafenib plus cetuximab; he co-founded Agendia and developed MammaPrint.
| Title | Journal | Year |
|---|---|---|
| Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR | Nature | 2012 |
Pages like this
not linked directly; found by shared links- PersonRyan B. Corcoran
Shares Encorafenib, BRAF, EGFR, Colorectal cancer.
- PersonJosep Tabernero
Shares Encorafenib, BRAF, EGFR, Colorectal cancer.
- PairingBRAF inhibitor + MEK inhibitor
Shares Encorafenib, BRAF, Colorectal cancer.
- IdeaPre-consented cohorts that can be randomised to future trials (TwiCs)
Shares Netherlands Cancer Institute (NKI-AvL), HR-positive / HER2-negative breast cancer, Colorectal cancer.
- TrialBREAKWATER
Shares Encorafenib, BRAF, EGFR, Colorectal cancer.
- PersonElena Élez
Shares Encorafenib, BRAF, Colorectal cancer.
- PairingGene-expression assay → chemotherapy omission
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.
- TrialCOLUMBUS
Shares Encorafenib, BRAF.